Deep Pharma Intelligence December 2022 Newsletter

Welcome to the December 2022 edition of our Deep Pharma Intelligence (DPI) newsletter.

In this month’s newsletter, we’d like to showcase some of our recent developments in putting our decisive, foundational vision into practice during the past month. These developments include

• The publication of our ‘Cancer Vaccines Industry Overview Q4, 2022’ analytical report – a comprehensive overview of the current state of the cancer vaccines market and research field.
• The publication of our ?‘Modern Technologies for Preclinical and Clinical Optimisation’ analytical report – an overview of the current state of research into 3D in vitro models and the market surrounding this technology.
• The unveiling of the Deep Pharma Intelligence Big Data Analytics Dashboard – an analytical tool that brings together companies, investors, collaborations, clinical trials, publications, news, and a host of other valuable sources of information on the implementation of AI in drug discovery.?

What’s next? Stay tuned and subscribe for further updates on these and related topics of interest in our upcoming newsletters. And as always, DPI remains open to dialogue, partnership proposals, and other forms of collaboration and cooperation on the topics of Pharma and BioTech with like-minded individuals and organisations across technology, science, finance, and investment.

If you have something that you think might be of interest to us, let us know at [email protected]

In the meantime, take a brief walk with us and explore the key take-aways from our activities below development.

Cancer Vaccines Industry Overview Q4, 2022

The recent development of numerous strategies, including vaccines, has greatly advanced research in cancer immunotherapy, and cancer vaccine development has shifted towards more specific tumour targeting. Interest in cancer vaccines is continually growing, and there was an outburst of interest in 2021. In 2021, the cancer vaccine market size was estimated at $10.72 billion, reaching $16.47 billion in 2022.?

Our ‘Cancer Vaccines Industry Overview Q4, 2022’ analytical report is a comprehensive overview of the current state of research and the market for cancer vaccines. The report’s key features are:

• A comprehensive overview of five high-impact cancer vaccine platforms
• 200 companies and R&D centres currently developing cancer vaccines
• A database with the key market players in cancer vaccine development
• An in-depth analysis of cancer vaccine delivery systems
• An overview of a selection of clinical trials for each cancer vaccine platform

To learn more, check out our latest Landscape Overview of the Cancer Vaccine Industry

If you would like your company to be featured in our report, please contact us at ?[email protected]

Modern Technologies for Preclinical and Clinical Optimisation

The application of state-of-the-art methods to the optimisation of preclinical and clinical trials enables researchers to reduce costs, obtain more reliable results, and conduct more sophisticated experiments. The main current directions for the optimisation of preclinical and clinical trials are robotic liquid handling, microfluidics, organoids, and organ-on-a-chip technologies. The market for these technologies was worth $2.98 billion in 2021, rising to $3.7 billion in 2022.?

Our new report, ‘Modern Technologies for Preclinical and Clinical Optimisation’, is an overview of the current state of research into 3D in vitro models and the market surrounding this technology. The report reviews the limitations, fields of application, and production techniques of 3D models and their advantages compared to 2D cell cultures. It delivers advanced market profiling, interactive mindmaps, information about companies and investors, technology application use cases, and other actionable information. The report’s key features include:

• A comprehensive overview of different 3D in vitro models
• Information on 160 companies and R&D centres that are currently developing 3D in vitro models and lab automation technologies
• A database with key market players in the development of organoids and organ-on-a-chip models
• An in-depth comparison of existing 3D in vitro models, animal models, and 2D cultures
• An overview of a selection of companies that are currently developing organoids, organ-on-a-chip models, or methods of lab automation

Follow this link for more information on modern technologies in preclinical and clinical studies as of Q4 2022.

If you would like your company to be featured in our report, please contact us at ?[email protected]

Big Data Analytics Dashboard

DPI has developed an analytical tool known as the Big Data Analytics Dashboard. The Dashboard is a collection of information on more than 500 companies, 1,000 investors, 100 collaborations, various clinical trials, publications, news, and a huge amount of other valuable information on the implementation of AI in drug discovery. The Dashboard is based on more than 170 parameters, allowing for the analysis of the financial position, marketing efforts, business development, intellectual property, product development, and many other aspects of the companies included in its analysis.?

The Dashboard provides insights into emerging areas of medical research and technology, including pharmaceuticals, BioTech, medical devices, and HealthTech. industries. Our Dashboard is updated every day to keep you informed about the latest changes in the industry.

The Dashboard’s applications include:

• Selection of companies by various parameters
• Investment landscape profiling
• Automatic AI-based SWOT analysis of companies and technological sectors
• Identification and analysis of competitors
• Comparative analysis of each company in the Dashboard’s database
• An Interactive Chart Builder allowing the user to create charts based on their desired parameters
• A portfolio constructor

For a detailed overview of the companies and technologies, check out our dashboard here.